The said batches have successfully passed all the checks for quality parameters both at the Gamaleya Center in Russia and at the Central Drug Laboratory, Kasauli in India
2-DG was developed by the Institute of Nuclear Medicine & Allied Sciences (INMAS), a laboratory of the Defence Research and Development Organisation (DRDO), in collaboration with Dr. Reddy's
This will enable Mangalam to reduce its reliability on Chinese imports for this product and also help to maintain an uninterrupted supply chain to a great extent
Natco has withdrawn its application filed with the Indian Patent Office, seeking Compulsory License against Lilly for Baricitinib for Covid-19 in India
The agreement will help ensure wider reach and access to patients in India
Baricitinib is used in combination with remdesivir for the treatment of suspected or laboratory confirmed COVID-19
The drug accumulates in the virus infected cells and prevents virus growth by stopping viral synthesis and energy production
Baricitinib was issued a restricted emergency use approval by the Central Drugs Standard Control Organization (CDSCO)
Baricitinib is an oral medication that was earlier registered in India for the treatment of moderate to severe active rheumatoid arthritis in adult patients.
As of 2nd May 2021, the Government has provided more 16.54 crore COVID-19 vaccine doses to States/UTs free of cost
Subscribe To Our Newsletter & Stay Updated
